Machine Learning-Based Deep Phenotyping of Atopic Dermatitis: Severity-Associated Factors in Adolescent and Adult Patients.


Journal

JAMA dermatology
ISSN: 2168-6084
Titre abrégé: JAMA Dermatol
Pays: United States
ID NLM: 101589530

Informations de publication

Date de publication:
01 Dec 2021
Historique:
pubmed: 11 11 2021
medline: 26 3 2022
entrez: 10 11 2021
Statut: ppublish

Résumé

Atopic dermatitis (AD) is the most common chronic inflammatory skin disease and is driven by a complex pathophysiology underlying highly heterogeneous phenotypes. Current advances in precision medicine emphasize the need for stratification. To perform deep phenotyping and identification of severity-associated factors in adolescent and adult patients with AD. Cross-sectional data from the baseline visit of a prospective longitudinal study investigating the phenotype among inpatients and outpatients with AD from the Department of Dermatology and Allergy of the University Hospital Bonn enrolled between November 2016 and February 2020. Patients were stratified by severity groups using the Eczema Area and Severity Index (EASI). The associations of 130 factors with AD severity were analyzed applying a machine learning-gradient boosting approach with cross-validation-based tuning as well as multinomial logistic regression. A total of 367 patients (157 male [42.8%]; mean [SD] age, 39 [17] years; 94% adults) were analyzed. Among the participants, 177 (48.2%) had mild disease (EASI ≤7), 120 (32.7%) had moderate disease (EASI >7 and ≤ 21), and 70 (19.1%) had severe disease (EASI >21). Atopic stigmata (cheilitis: odds ratio [OR], 8.10; 95% CI, 3.35-10.59; white dermographism: OR, 4.42; 95% CI, 1.68-11.64; Hertoghe sign: OR, 2.75; 95% CI, 1.27-5.93; nipple eczema: OR, 4.97; 95% CI, 1.56-15.78) was associated with increased probability of severe AD, while female sex was associated with reduced probability (OR, 0.30; 95% CI, 0.13-0.66). The probability of severe AD was associated with total serum immunoglobulin E levels greater than 1708 IU/mL and eosinophil values greater than 6.8%. Patients aged 12 to 21 years or older than 52 years had an elevated probability of severe AD; patients aged 22 to 51 years had an elevated probability of mild AD. Age at AD onset older than 12 years was associated with increased probability of severe AD up to a peak at 30 years; age at onset older than 33 years was associated with moderate to severe AD; and childhood onset was associated with mild AD (peak, 7 years). Lifestyle factors associated with severe AD were physical activity less than once per week and (former) smoking. Alopecia areata was associated with moderate (OR, 5.23; 95% CI, 1.53-17.88) and severe (OR, 4.67; 95% CI, 1.01-21.56) AD. Predictive performance of machine learning-gradient boosting vs multinomial logistic regression differed only slightly (mean multiclass area under the curve value: 0.71 [95% CI, 0.69-0.72] vs 0.68 [0.66-0.70], respectively). The associations found in this cross-sectional study among patients with AD might contribute to a deeper disease understanding, closer monitoring of predisposed patients, and personalized prevention and therapy.

Identifiants

pubmed: 34757407
pii: 2785834
doi: 10.1001/jamadermatol.2021.3668
pmc: PMC8581798
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1414-1424

Auteurs

Laura Maintz (L)

Department of Dermatology and Allergy, University Hospital Bonn, Venusberg-Campus 1, Germany.
Christine Kühne-Center for Allergy Research and Education Davos (CK-CARE), Davos, Switzerland.

Thomas Welchowski (T)

Christine Kühne-Center for Allergy Research and Education Davos (CK-CARE), Davos, Switzerland.
Department of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Venusberg-Campus 1, Germany.

Nadine Herrmann (N)

Department of Dermatology and Allergy, University Hospital Bonn, Venusberg-Campus 1, Germany.
Christine Kühne-Center for Allergy Research and Education Davos (CK-CARE), Davos, Switzerland.

Juliette Brauer (J)

Department of Dermatology and Allergy, University Hospital Bonn, Venusberg-Campus 1, Germany.
Christine Kühne-Center for Allergy Research and Education Davos (CK-CARE), Davos, Switzerland.

Anna Sophie Kläschen (AS)

Department of Dermatology and Allergy, University Hospital Bonn, Venusberg-Campus 1, Germany.
Christine Kühne-Center for Allergy Research and Education Davos (CK-CARE), Davos, Switzerland.

Rolf Fimmers (R)

Department of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Venusberg-Campus 1, Germany.

Matthias Schmid (M)

Department of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Venusberg-Campus 1, Germany.

Thomas Bieber (T)

Department of Dermatology and Allergy, University Hospital Bonn, Venusberg-Campus 1, Germany.
Christine Kühne-Center for Allergy Research and Education Davos (CK-CARE), Davos, Switzerland.

Peter Schmid-Grendelmeier (P)

Christine Kühne-Center for Allergy Research and Education Davos (CK-CARE), Davos, Switzerland.
Allergy Unit, Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland.

Claudia Traidl-Hoffmann (C)

Christine Kühne-Center for Allergy Research and Education Davos (CK-CARE), Davos, Switzerland.
Department of Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Institute of Environmental Medicine, Helmholtz Zentrum Muenchen, Augsburg, Germany.

Cezmi Akdis (C)

Christine Kühne-Center for Allergy Research and Education Davos (CK-CARE), Davos, Switzerland.
Swiss Institute of Allergy and Asthma Research (SIAF), Davos, Switzerland.

Roger Lauener (R)

Christine Kühne-Center for Allergy Research and Education Davos (CK-CARE), Davos, Switzerland.
Children's Hospital of Eastern Switzerland, St Gallen, Switzerland.

Marie-Charlotte Brüggen (MC)

Christine Kühne-Center for Allergy Research and Education Davos (CK-CARE), Davos, Switzerland.
Allergy Unit, Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland.
Faculty of Medicine, University of Zurich, Zürich, Switzerland.

Claudio Rhyner (C)

Christine Kühne-Center for Allergy Research and Education Davos (CK-CARE), Davos, Switzerland.

Eugen Bersuch (E)

Allergy Unit, Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland.

Ellen Renner (E)

Translational Immunology in Environmental Medicine, School of Medicine, Technical University of Munich, Munich, Germany.
Hochgebirgsklinik Davos, Davos, Switzerland.

Matthias Reiger (M)

Christine Kühne-Center for Allergy Research and Education Davos (CK-CARE), Davos, Switzerland.
Department of Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Institute of Environmental Medicine, Helmholtz Zentrum Muenchen, Augsburg, Germany.

Anita Dreher (A)

Christine Kühne-Center for Allergy Research and Education Davos (CK-CARE), Davos, Switzerland.

Gertrud Hammel (G)

Christine Kühne-Center for Allergy Research and Education Davos (CK-CARE), Davos, Switzerland.
Department of Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Institute of Environmental Medicine, Helmholtz Zentrum Muenchen, Augsburg, Germany.

Daria Luschkova (D)

Christine Kühne-Center for Allergy Research and Education Davos (CK-CARE), Davos, Switzerland.
Department of Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Institute of Environmental Medicine, Helmholtz Zentrum Muenchen, Augsburg, Germany.

Claudia Lang (C)

Allergy Unit, Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH